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Abstract  
Introduction Early nutritional intervention with partially-hydrolyzed whey-based formula (PHF-W) 
instead of standard cow’s milk formula (CMF) has been found to reduce the risk of atopic dermatitis 
(AD) development in non-exclusively breastfed infants with familial heredity of AD. 
Objective To estimate the 6-year economic impact of this nutritional intervention in non-exclusively 
breastfed Indonesian urban infants with family history of AD. 
Methods A mathematical model simulated AD incidence and burden of using PHF-W vs. CMF in the 
target population from birth to age 6. The model integrated literature, current cost and market 
catalogues, and expert clinician opinion. Modelled outcomes included AD risk, time spent post-AD 
diagnosis, days without flare, quality-adjusted life-years, and costs. 
Results Using PHF-W instead of CMF resulted in an estimated absolute 14% (95% CI: 4%, 23%) AD 
risk reduction, a 0.69 year (95% CI: 0.26, 1.13) per-child reduction in time spent post-AD diagnosis, 
a 38 (95% CI: 12, 67) increase in days without AD flare, and a 0.046 gain in quality-adjusted life-
years. The AD-related 6-year cost estimates when feeding high-risk urban infants with PHF-W were 
Indonesian Rupiah (IDR) 8,695,057 (95% CI: IDR 4,519,447, IDR13,995,605) and IDR13,139,569 (95% 
CI: IDR 7,098,794, IDR 19,216,068) per child, respectively, resulting in a net per-child difference of 
IDR 4,444,512 (95% CI: IDR1,893,080, IDR 8,557,946) favoring PHF-W. 
Conclusion PHF-W for the first 17 weeks of non-exclusively breastfed Indonesian urban infants with 
a hereditary risk of AD demonstrated a reduction in AD incidence, increased days without flare, and 
increased quality-adjusted life-years and net cost reductions. 
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Introduction 
 
Atopic dermatitis (AD) is a common inflammatory 
skin disorder that most commonly occurs during 
infancy.1,2 Often a chronic disorder, AD imposes a 
substantial economic and quality of life (QoL) 
burden on children, caregivers, and society.3-7  
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In Indonesia, AD incidence was 11% among infants 
aged 0-4 months.8 Available estimates of the annual 
cost of AD per child in Asia range from $199 in 
Thailand9 to USD3,522 (direct cost only: 
USD1,253) in patients receiving care at allergy 
clinic in South Korea10 (all figures inflated to 2012-
2013 and converted to USD). 
AD is affected by various genetic, 
immunologic, and environmental factors. For 
example, in Indonesia, infants with family atopy 
were over 22 times as likely of developing AD 
compared to infants with no family history.8 
Exposure to allergens, such as proteins within 
standard cow’s milk formula (CMF), can increase 
the risk of AD in infants. Despite recommendations 
to exclusively breastfeed infants in the first 6 months 
of life,11-13 formula feeding with CMF is often used 
as a nutritional supplement or replacement for breast 
milk. In high-risk infants with first degree heredity 
of AD (i.e., those with ≥1 parent or sibling with 
history of allergic disease14-16), such exposure to 
cow’s milk may result in a greater risk of AD 
development.  
Partially or extensively hydrolyzed formulas 
are two alternative protein sources that have been 
shown to reduce the risk of AD and other 
allergies17,18 compared to CMF in these high-risk 
infants.14,19,20 In particular, the German Infant 
Nutritional Intervention (GINI) trial found that non-
exclusively breastfed infants with atopic heredity 
randomized to whey-based partially hydrolyzed 
formulas (PHF-W) for their first 4 months 
experienced a lower cumulative incidence of AD 
relative to CMF 6 years following birth (27.4% vs. 
39.1%, adjusted RR=0.64; 95% CI: 0.48-0.86).14 On 
the basis of such data, several national and 
international allergy organizations have suggested 
hydrolyzed formulas as an allergy risk reduction 
strategy for these high-risk infants.16,21-23 As 
demonstrated previously, the potentially higher 
costs of PHF-W relative to CMF during the 17-week 
interventional period should be partially offset by 
the direct and indirect cost savings and QoL 
improvements associated with the reduction in AD 
incidence in this high-risk population.24-31  
Using health economic modeling techniques 
that combine data from the GINI study (the largest 
comparative trial of infant formula in high risk 
infants),14 experts opinions, and local cost data, this 
study estimated the clinical and economic impact of 
an intervention consisting in feeding high-risk urban 
Indonesian infants with PHF-W instead of CMF for 
the first 17 weeks of life. The analysis was limited 
to the urban population because it is considered most 
likely to be consuming the infant formula evaluated 
herein. 
 
Methods 
 
Overview 
 
Mathematical modeling (i.e., Markov cohort 
techniques—an extension of life table analysis)32,33 
were used to compare costs and outcomes associated 
with AD development over time among those using 
PHF-W vs. CMF from birth to 17 weeks of life in 
non-exclusively breastfed urban Indonesian infants 
with first degree atopic hereditary risk. The 
experiences of the cohorts were simulated from birth 
to age six. The target population, risk reduction, 
formula feeding and duration, and age-specific AD 
incidence were selected on the basis of the GINI.14,19  
The analysis adopted a societal perspective 
and included direct medical, indirect (time loss), and 
out of pocket (transportation) costs associated with 
the prevention and treatment of AD. The primary 
outcomes for each treatment arm included the 
proportion of patients developing AD, the number of 
days with AD flare, the time spent post-AD 
diagnosis, quality adjusted life years (QALYs), and 
costs.  
The simplified model structure is presented 
in Figure 1; urban infant cohorts entered the model 
at birth and were followed in bi-weekly cycles until 
age 6. Infants were initiated on CMF or PHF-W for 
the first 17 weeks of life (as in GINI) until 12 months 
of age or the development of AD. Similar to 
previous published models on this topic24-26,28,30,31,34, 
three treatment approaches were possible after initial 
development of AD, as confirmed by Indonesian 
pediatricians with AD treatment experience (authors 
AS and ZM). The first approach involved a switch 
in feeding formula, including a switch to extensively 
hydrolyzed formula (EHF), soy or amino acid. This 
approach was used among infants ≤ 12 months 
presenting with mild AD (in 100% of cases) or 
moderate AD (in 50% of cases). The second 
approach included pharmacological therapies and 
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was used among all children > 12 months regardless     
of severity at presentation. The third approach 
combined both changes in formula and 
pharmacological therapies and was used in 50% of 
infants ≤ 12 months presenting with mild AD and in 
all infants ≤ 12 months presenting with severe AD. 
Any infant formula use was assumed to end at 12 
months of age as nutrient requirements shift to solid 
foods by this age; hence, the pharmacological 
treatment is the only treatment pathway available 
post 12 months of age. If a child was treated with a 
formula switch and responded favorably, she/he was 
assumed to continue on that new formula until (a) 
reaching 12 months of age, (b) the next AD episode 
(i.e., flare), or (c) death. If a child was treated with 
pharmacotherapy, she/he was assumed to continue 
treatment until completion of the recommended 
course and remain on his/her initial formula.  
Treatment success was assessed every two 
weeks and was defined by a resolution of AD 
symptoms. Response rates determined the 
distribution of children who experience AD 
symptom resolution and hence the proportion of 
children transitioning to from the initial AD episode 
into a so-called “AD-controlled state” (ADCS). 
Response rates varied according to AD severity, 
treatment approach, and the line of treatment.  
Finally, a child could experience subsequent 
relapse(s) (i.e., flare[s]) following period(s) of 
ADCS as determined based upon age and AD 
severity.  
 
 
 
Figure 1. Simplified Presentation of the Model Structure 
Arrow key: Dash is response; Dot is flare; Dash/Dot combination is no response. 
Abbreviations: AD, atopic dermatitis; ADCS, atopic dermatitis controlled state; CMF, standard cow’s milk formula; PHF-
W, partially hydrolyzed whey formula. 
Schematic diagram of the Markov decision model for healthy children at high risk for AD. Children not exclusively breastfed 
with a family history of allergy enter into the model at birth [A] and initiate a 4-month course of PHF-W or CMF [B]. 
Children who develop AD [C] are treated by 1 of 3 approaches: formula change only [D], formula change combined with 
first-line pharmacotherapy [E], or first-line pharmacotherapy only [F]. After first-line treatment, children either enter into 
the ADCS or, if no response is seen, have a change in treatment regimen [G-N]. 
 World.Nutr.Journal | 46  
Inputs 
 
Epidemiologic inputs are provided in Table 1. 
Probability of initial AD development and 
subsequent flares obtained from the GINI study14 
were stratified by severity (i.e., mild, moderate, and 
severe) and age (i.e., 0-1 years; >1-6 years). The 
biweekly probabilities of AD for PHF-W and CMF 
were obtained using linear interpolation of the 1, 3, 
and 6 year cumulative incidence data from the GINI 
study.14 Table 2 provides the clinical management 
and treatment effectiveness inputs, including AD 
management modalities and response rates by AD 
severity, treatment line, and age group. 
Daily formula intake was age adjusted for 
nutrient needs from birth to 12 months by means of 
a previously-reported method25 that accounted for 
partial breast feeding. Formula acquisition costs 
(IDR 129,000 for a 400g can of PHF-W; IDR 91,800 
for a 650g can of CMF; IDR 167,139 for a 400g can 
of soy; 417,000 for 400g of EHF; and 490,000 for 
400g of amino acid) were based on the price and 
market share in Indonesia (Source: Packaged Food: 
Euromonitor from trade sources/national statistics, 
February 2013). Recommended quantities from the 
package inserts were used to determine quantity of 
formula for daily consumption. The analysis took 
into account the additional, incremental cost that 
Table 1. Epidemiologic Inputs 
 Base Case Value in uSA PSA Distribution 
Low High 
Probability of AD: CMF‡  
0 to 1 year 16.80% 6.96% 29.85% Beta 
1 to 3 years 20.07% 9.00% 34.19% Beta 
3 to 6 years 8.42% 0.18% 29.66% Beta 
RR of AD (cumulative) (PHF-W vs. CMF) ‡  
0 to 1 year 0.54 0.33 0.89 Lognormal 
1 to 3 year 0.57 0.36 0.90 Lognormal 
3 to 6 year 0.82 0.40 1.70 Lognormal 
Distribution of cases by severity at initial 
presentation: 0-1 years§  
Mild AD 50.00% 46.20% 53.80% Beta 
Moderate AD 40.00% 46.67% 32.91% Beta 
Severe AD 10.00% 7.13% 13.28% Beta 
Distribution of cases by severity at initial 
presentation: >1 years§  
Mild AD 60.00% 56.05% 63.88% Beta 
Moderate AD 30.00% 36.81% 22.83% Beta 
Severe AD 10.00% 7.13% 13.28% Beta 
Probability of flare recurrence over 12 weeks: 
0-1 years§ 
 
Mild AD 30.00% 24.83% 35.44% Beta 
Moderate AD 50.00% 39.99% 60.01% Beta 
Severe AD 75.00% 33.41% 98.53% Beta 
Probability of flare recurrence over 12 weeks: 
>1 years§ 
 
Mild AD 10.00% 8.39% 11.74% Beta 
Moderate AD 30.00% 24.83% 35.44% Beta 
Severe AD 50.00% 39.99% 60.01% Beta 
Mortality ǁ 0.0310%    
 
Abbreviations: AD, atopic dermatitis; CMF, standard cow’s milk formula; PHF-W, partially-hydrolyzed whey-based 
formula; PSA, probabilistic sensitivity analysis; RR, relative risk; uSA, univariate sensitivity analyses. 
‡ Source: von Berg et al. 2008 for PHF-W vs. CMF14 
§ Source: Expert panel 
ǁ Source: Mortality data for children under 5 (Source: World Bank data) 
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would be incurred as a result of feeding with 
alternative infant formula (such as PHF-W, soy-
based formula, and EHF).  
The two experts (authors AS and ZM) 
provided assumptions on the type and amount of 
resources used with each treatment modality based 
on severity of AD (Table 3). Table 3 also provides 
costs information. For inpatient/outpatient visits and 
diagnostic tests, average fees charged in Indonesian 
hospitals or laboratories where information was 
available were used. Emollients and or moisturizer 
creams were utilized by all AD patients both during 
and between flares. Pharmacotherapies acquisition 
costs were obtained from an online drug information 
tool (http://www.mims.com/Indonesia) commonly 
used in Indonesia. To be conservative, the lowest 
available drug price was used if more than one 
option was available. Reduced productivity (i.e., 
indirect costs) included lost time to care of AD 
children following the initial physician visit (4 
hours) and 2 hours per visit thereafter. 
Transportation costs to and from each physician 
visits were also included in the analysis.  
Based on previously published data, young 
children who do not have AD were assumed to 
experience a utility of 1.000, but that those in ADCS 
after an episode had a utility of 0.980 to recognize 
that mild, subclinical episodes could permanently 
reduce QoL.35,36 The utilities associated for a mild, 
moderate, and severe AD episodes were 0.863, 
0.690, and 0.450, respectively. Death was associated 
with a utility of zero.  
 
Analysis 
 
Using the model structure and inputs as detailed, 
several incremental cost effectiveness ratios 
(ICERs) were computed to estimate the economic 
value of PHF-W vs. CMF. These outcomes included 
the incremental costs per AD case avoided, per 
day(s) with flare avoided, and QALY gained. In 
addition, the cost of AD per patient with AD (overall 
and per year) and the number of annual AD visits per 
patient with AD were also derived from the model 
to allow comparisons of these values with previous 
published estimates, as a way to validate the present 
analysis.   
Table 2. Clinical Management and Effectiveness Inputs 
Variable Base Case 
Value in uSA PSA 
Distribution Low High 
Response rate to change of formula in PHF-W cohort 50% 40% 60% Beta 
Response rate to change of formula in CMF cohort 80% 18% 100% Beta 
Response rate to combination treatment   
1st-line Moderate AD  70% 19% 99% Beta 
2rd-line Moderate AD 70% 19% 99% Beta 
3rd-line Moderate AD 70% 19% 99% Beta 
1st-line Severe AD  55% 43% 67% Beta 
2nd-line Severe AD 55% 43% 67% Beta 
3rd-line Severe AD 55% 43% 67% Beta 
Response rate to 1st-line pharmacotherapy  
Mild AD 100% 100% 100% NA 
Moderate AD 50% 40% 60% Beta 
Severe AD 50% 40% 60% Beta 
Response rate to 2nd-line pharmacotherapy  
Mild AD 85% 51% 100% NA 
Moderate AD 90% 66% 100% Beta 
Severe AD 90% 66% 100% Beta 
Abbreviations: AD, atopic dermatitis; CMF, standard cow’s milk formula; PHF-W, partially-hydrolyzed whey-based 
formula; PSA, probabilistic sensitivity analysis; uSA, univariate sensitivity analyses. 
Source: Expert panel 
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Sensitivity analyses evaluated the robustness 
of the results. Univariate sensitivity analyses (uSA) 
varied individual model parameters while keeping 
other base-case values unchanged (see Tables 1-3 
for ranges). Scenario analyses were conducted to test 
the impact of changing key model assumptions 
either alone or in combination. These included 
omitting any flares from the analysis and restricting 
the analysis to 1 year (as opposed to the 6-year time 
frame). Multivariate, probabilistic sensitivity 
analysis (PSA) was conducted whereby the models 
were run 5,000 times via the Monte Carlo simulation 
to estimate so-called bootstrapped 95% “credible 
intervals” (95% CIs).  
In accordance with common health 
economics research guidelines, clinical and 
economic outcomes occurring after the first year 
were discounted at 3% per annum to estimate the net 
Table 3. Price and Quantities of Resources Used Treat AD by Severity at Presentation  
  
Cost per 
unit† Use per AD patient 
  Mild  Moderate  Severe  
Number of physician visits§   
At diagnosis 150,000 1.00 visit, regardless of severity  
Follow up  
   <12 months of age 150,000 1.00 visit / month until month 6, 1.00 visit / 
2 months from month 6 to month 12, all 
regardless of severity 
   ≥12 months of age 150,000 1.00 visit / 3 months, regardless of severity 
Number of hospitalizations (at initial 
diagnosis)§ 
 
Any age 500,000 0.00 0.00 0.10 
Number of diagnostic tests (at initial 
diagnosis)§ 
 
   
Specific IgE test (≤3 years) 259,000 1.00 1.00 1.00 
Skin prick test (>3 years) 425,000 1.00 1.00 1.00 
Pharmacotherapy units per child with AD (at 
initial diagnosis and in case of flare or non-
response)‡ 
 
Emollient cream (40 g/unit) 80,000 3.00 3.00 3.00 
Antibiotic oral 50 mL (<12 months of age) 50,000 0.00 0.00 0.50 
Antibiotic oral 300 mg x 30's (≥12 months of 
age) 
326,345 0.00 0.00 0.50 
Antibiotic Topical 2% x 10g x 1's 54,000 0.00 1.50 2.25 
Antihistamines 5 mg x 30's 110,000 0.00 0.50 0.75 
Corticosteroid - oral 16 mg x 5 x 6's 162,000 0.00 0.00 0.12 
Corticosteroid - topical 10g x 1's (tube) 54,500 0.00 1.00 1.50 
Immunosuppressants 25 mg x 5 x 10's 763,665 0.00 0.00 0.60 
Pimecrolimus 1g x 1's (tube) 139,125 0.00 0.00 1.00 
Special wash care 100g bar of soap (per flare)  31,000 2.00 2.00 2.00 
Other costsǁ   
Hours lost to attend initial care  714.15 4.00 4.00 4.00 
Hours lost per physician visit  714.15 2.00 2.00 2.00 
Trip per physician visit 35,880 1.00 1.00 1.00 
Abbreviations: AD, atopic dermatitis; IDR, Indonesian Rupiah; IgE, immunoglobulin E 
Source: Expert opinion. 
† Varied by ±25% in univariate and multivariate sensitivity analyses (via uniform distributions).   
‡ Costs obtained from MIMS (http://www.mims.com/Indonesia/home/Index).  
§ Costs are based on average fees charged in Indonesia.  
ǁ Costs associated with the time loss were estimated using average hourly wages in Indonesia, labor force participation, and 
hours spent was obtained from the expert panel and is based on their experience of treating AD patients. 
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present value of the different strategies, to reflect 
society’s preference for the present. All costs 
reported in this study represent 2013 values, 
expressed in Indonesian Rupiah (IDR) 
(IDR100,000=USD7.58 as of May 12, 2015). 
 
Results 
 
CMF was associated with higher AD incidence 
(+14%) compared to PHF-W (CMF 39% vs. PHF-
W 25%), less AD days (58 vs. 96), and fewer years 
(-0.69) in a post-AD diagnosis state (1.69 vs. 1.00). 
Discounted QALYs were 5.454 with PHF-W versus 
5.500 for CMF, for a net difference of 0.046 (Table 
4). All differences were predicted to be significant 
on the basis of the PSA, as indicated by the 95% CI 
(Table 4).  
The total discounted costs (direct and 
indirect) among the non-exclusively breastfed 
infants with atopic heredity were lower among those 
fed with PHF-W formula (IDR 8,695,057; or 
USD659) compared to those in the CMF group (IDR 
13,139,569; or USD996). Primary drivers of total 
costs were those associated with pharmacological 
treatments followed by indirect costs and physician 
visits. The resulting 6-year net savings due to risk 
reduction of AD with PHF-W was IDR 4,445,512 
(USD337) (Table 4). Comparison of PHF-W versus 
CMF using ICER values showed PHF-W to be a net 
cost saving strategy that also resulted in reductions 
of AD cases and gains in AD-free days and QALYs. 
Thus, PHF-W was the “dominant” strategy (i.e., 
more effective and less expensive) relative to CMF 
(Table 4).  
Table 4. Results 
  PHF-W arm CMF arm Difference 
Discounted Costs (IDR)   
Formula prevention 783,291 -- 783,291 
Formula treatment 495,843 674,119 -178,276 
Physician visits 334,329 563,353 -229,025 
Pharmacotherapy 6,928,005 11,655,352 -4,727,347 
Diagnostic testing 68,903 104,210 -35,307 
Hospitalization 1,196 1,886 -690 
Indirect costs 83,491 140,649 -57,158 
Total costs (95% CI)‡ 
8,695,057 13,139,569 -4,444,512 
(4,519,447, 
13,995,605) (7,098,794, 19,216,068) 
(-8,557,946, -
893,080) 
Discounted Costs (in USD) USD 659 USD 996 -USD 337 
Clinical effects   
Proportion of children developing AD 
(95% CI) ‡ 
25% 39% -14% 
(0.13, 0.43) (0.23, 0.54) (-0.23, -0.04) 
Years of life post AD diagnosis (95% 
CI)‡ 
1.00 1.69 -0.69 
(0.56, 1.67) (1.04, 2.43) (-1.13, -0.26) 
Days with AD symptoms (95% CI)‡ 58 96 -38 (29, 95) (53, 142) (-67, -12) 
Discounted QALYs (95% CI)‡ 5.500 5.454 0.046 (5.418, 5.537) (5.332, 5.514) (0.014, 0.103) 
ICER (Discounted)    
Cost per AD-case avoided     Dominant § 
Cost per AD-free day gained     Dominant § 
Cost per QALY gained     Dominant § 
Abbreviations: AD, atopic dermatitis; IDR, Indonesian Rupiah; CMF, standard cow’s milk formula; PHF-W, partially-
hydrolyzed whey-based formula; QALY, quality adjusted life-year. 
Base-case results are presented in the table above for an average healthy formula-fed infant with a positive family history of 
allergy (high-risk of developing AD). 
‡Percentile distributions (2.5th and 97.5th) for the parameters selected to represent the uncertainty surrounding the mean value 
of the parameter. 
§ Dominance refers to a situation where one intervention (PHF-W in this study) is said to dominate another (CMF in this 
study) when its effectiveness is found to be higher and the costs lower. 
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PSA also indicated that PHF-W was dominant in 
almost all 5,000 model runs (Figure 2).In uSA, the 
relative risk of AD between PHF-W and CMF, and 
the probability of AD with CMF, had the largest 
influence on the difference in cost between PHF-W 
and CMF. Other variables with potentially minor 
effect on net cost savings were the costs of PHF-W, 
CMF, and emollients. Finally, in one scenario 
analysis, it was conservatively assumed that no AD 
patient would experience a recurrence. In that case, 
PHF-W remained cost dominant (i.e., resulting in a 
net discounted cost saving of IDR 3,545,058, 3 
additional AD-symptom-free days, and discounted 
QALY gains of 0.014).  
Finally, AD development at any time within 
the first 6 years of life was predicted to result in an 
undiscounted total (direct and indirect) AD cost of 
approximately IDR 35,600,000 (i.e., USD2,700) 
over this period. The estimated average annualized 
undiscounted total (direct and indirect) cost for an 
infant developing AD at any time within the first 6 
years of life was approximately IDR 8,500,000 (i.e., 
USD645) (including IDR 8,443,175 [USD640] in 
direct costs alone). The total annual number of visits 
per AD case was estimated to be approximately 2.47   
(across all severity levels). 
 
Discussion 
 
This model shows that an early nutritional 
intervention with PHF-W in urban and non-
exclusively breastfed Indonesian infants with first-
degree atopic heredity offers favorable AD risk 
reduction, fewer AD days with flare, and more 
QALYs compared to CMF while reducing costs. 
The robustness of these results was confirmed via 
sensitivity analyses. 
The cost differential between the two 
formulas was driven by the incidence of AD in each 
arm and the costs associated with pharmacotherapy. 
Other variables and costs had minimal impact. The 
cost of pharmacotherapy was high because it was the 
most common and expensive treatment method. In a 
study reviewing awareness and practice of AD 
management among 255 dermatologists in 
Southeast Asian countries, pharmacotherapy had a 
 
Figure 2. Scatterplot of Difference in Costs and QALYs Resulting from Multivariate PSA 
Each black dot represents 1 of the 5000 multivariate PSA simulations. 
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high rate of use in all countries (i.e., Philippines, 
Vietnam, Thailand, Malaysia, Singapore, and 
Indonesia) reviewed.37 Moisturizers were used 
frequently, with over 79% of respondents in 
Indonesia having used moisturizers in any given 
phase of treatment,37 consistent with the use of 
emollients assumed in this analysis.  
This analysis was limited by a lack of 
published data on Indonesia AD epidemiology and 
treatment patterns in at risk urban infants with first 
degree AD heredity. The impact of PHF-W and 
CMF on AD incidence has also not been specifically 
studied in urban Indonesian infants. Consequently, 
we relied on the results of GINI14 as the best source 
of data given its standing as the largest and longest 
intervention trial on PHF-W and CMF to date.20,38 
The cumulative AD incidence rates observed in 
GINI for PHF-W and CMF are also consistent with, 
if not perhaps more conservative than, those 
observed in a smaller Southeast Asian study by Chan 
et al, 2002 (N=110) in genetically predisposed 
Singaporean infants.39 Specifically, cumulative AD 
incidence in the CMF and PHF-W arms at 24 
months of age in this Southeastern Asian study was 
43.9% and 22.6%, respectively (an absolute 
difference of 21.3 percentage points; odds 
ratio=0.37, P=0.019).39 Corresponding rates in GINI 
were 33.5% and 19.4%, respectively (an absolute 
difference of 14 percentage points; adjusted 
RR=0.57, 95% CI: 0.36-0.90).14  
Little evidence is available regarding the 
severity of AD in Indonesia and elsewhere. In the 
present analysis, it was assumed that AD would be 
moderate and severe in 40% and 10% of cases in 
children aged <1 year, respectively, and in 30% and 
10% of cases in children aged 1-6 years, 
respectively. In the International Study of Asthma 
and Allergies in Childhood (ISAAC),40 severe AD 
(defined as current eczema associated with sleep 
disturbance 1 or more nights per week) accounted 
for 11% of AD cases in those aged 6 to 7 years old. 
In a survey of knowledge, attitudes, and practices of 
Southeast Asian dermatologists in the management 
of AD,37 mild and moderate cases accounted for 
65% and 35% of patients, respectively. Thus, the 
assumptions used herein may be considered 
reasonable given the population considered (i.e., 
high-risk urban infants - defined as those having ≥1 
parent or sibling with history of allergic disease/first 
degree atopic heredity).  At the same time, it should 
be noted that the assumptions regarding both the 
severity and prevalence of AD may reflect the 
perspective adopted herein, which focuses on the 
urban, affluent population, which was expected to be 
most prone to use hydrolyzed infant formula. Thus, 
the outcomes of this analysis could have been 
substantially different had we adopted a rural or 
government practice perspective.  
Treatment patterns and assumptions 
regarding AD treatment effectiveness once a child 
developed AD were derived largely from the clinical 
opinion of three Indonesian physicians, reflecting 
the relative lack of Indonesian data on AD severity. 
This reliance on expert opinion is an important 
limitation of--but is not unique to--the present 
analysis. For instance, other cost-effectiveness 
analyses of hydrolyzed formula in Western 
countries24-30 have relied upon similar data 
collection methods and evidence standards adopted 
herein. In part, the reliance on expert opinion is 
dictated by the clinical diagnosis of AD and its 
subjective assessment of severity. Furthermore, AD 
diagnosis and management are not routinely 
recorded administratively for reimbursement 
purposes. Hence many AD treatments require out-
of-pocket expenditure borne by families. These may 
be under-recorded and are difficult to estimate.  
Despite these important limitations, it should 
be noted that the annual costs of AD IDR 8,500,000 
(i.e., USD645) are within a comparable range of 
estimates found in other developing Asian countries 
such as Thailand (USD199 for direct cost),9 
Malaysia (USD584 overall and USD398 in direct 
costs),41 the Philippines (USD359),31 or a recent 
estimate of annual treatment costs in patients aged 7 
years in low-income Asian countries including 
Indonesia (ranging from USD640 to USD929 
depending on the emollient used).42 While not 
directly comparable due to difference in income per 
capita, it is worth noting that the present estimates 
are not surprisingly much lower than estimates from 
higher income countries such as Singapore 
(USD1,212 including USD1,007 in direct costs 
alone),43 Australia (total costs: USD6,187, direct 
cost: USD4,842; AD patients from a dermatology 
clinic),6 or South Korea (total cost: USD3,522, 
direct cost: USD1,253; patients from an allergy 
clinic)10 (all figures inflated to 2012-2013 and 
converted to USD). These differences reflect 
variations in study design and methods, target 
patient populations, treatment patterns and per-
capita income.  
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The average number of physician visits per 
year needed for AD management (2.47) appears 
conservative compared with data from Thailand 
(approximately 4 to 5 visits overall)9 and in analyses 
similar to this one conducted for Singapore (3.51)43 
and Malaysia (6.88).41  
The relative consistency of present study’s 
estimates of both the annual cost of, and number of 
visits associated with, AD with previous research in 
lower income Asian countries as described above 
provide some reassurance that our estimates of the 
benefits of preventing AD with hydrolyzed infant 
formula are likely relatively robust despite 
uncertainty regarding AD treatment patterns in 
Indonesia.   
In some ways, one might consider that the 
present study is conservative in a number of aspects. 
First, incidence and effects of AD were exclusive 
within to the first 6 years of life only; given the 
chronic nature of AD, further burden is possible. 
Secondly, PHF-W could also have a protective 
effect to other allergic manifestations; impact of 
which is not captured here. Lastly, details on the  
impact on parents’ productivity and quality of life 
(as a result of poor night sleep to attend a crying 
child, etc.) was not captured in its entirety due to 
lack of data; compounded with the potential impact 
of AD of QoL could result in further additional cost 
savings to be realized.  
In conclusion, this model showed the long-
term cost-effectiveness of PHF-W nutritional 
intervention versus CMF in healthy urban infants 
with atopic heredity (high-risk) who are not 
exclusively breastfed from an Indonesian 
perspective. Results suggests that the use of PHF-W 
is superior to CMF as it reduces the clinical and QoL 
burden of AD while decreasing overall costs, even 
after the inclusion of formula costs. These results 
will be important to note by key payers in making 
decisions regarding reimbursement/coverage 
policies for formulas among at-risk urban infants. 
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